Today has officially been registered as Final Fantasy VII Day in Japan, to celebrate the anniversary of the game's release.
The day has been registered to celebrate the anniversary of the game’s releaseFinal Fantasy VII Day has been officially registered in Japan to celebrate the anniversary of the game.. As of 2022, it has sold almost 14 million copies.Yoshinori Kitase
wrote: “The 31st of January 1997, the day that Final Fantasy VII came out, was not just a significant day for the Final Fantasy series, but also marked when so many big things started moving for those of us who worked on the game. “I remember being overwhelmed at the breakneck speed with which video game technology was evolving, but also dreaming big things for the future.“With the establishment of this official anniversary day, I will now always remember these things, and hold them dearly in my heart.”As confirmed during the Final Fantasy 7 25th anniversary stream last year, Part 2 is scheduled for release on
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Is this the end for Final Fantasy on Xbox?Final Fantasy on Xbox was once but a dream, until the Xbox 360 generation saw Square finally start to show Xbox some love. Now, it feels like that spell might have run its course... have we seen the last of Final Fantasy on Xbox?
Read more »
Final day for people using non-smart energy meter to use £66 top-up voucherFinal day for people using non-smart energy meter to use £66 top-up voucher before it expires
Read more »
Australian GP releases more race day ticketsFans will have one last chance to score race day tickets to the F1 Australian Grand Prix next week.
Read more »
Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia - BMC NephrologyBackground Hyperkalemia (HK) is a barrier to optimization of renin-angiotensin-aldosterone system inhibitor (RAASi) therapy in heart failure (HF) and chronic kidney disease (CKD). We investigated cardiorenal risk associated with changes in RAASi regimen after an episode of HK in patients with HF and/or CKD. Methods This observational study utilized data from hospital records, claims, and health registers from the US (Optum’s de-identified Market Clarity Data) and Japan (Medical Data Vision). Included patients had an index episode of HK between July 2019 and September 2021 (US), or May 2020 and September 2021 (Japan), with prior diagnosis of HF or CKD (stage 3 or 4), and RAASi use. Risk of a cardiorenal composite outcome (HF emergency visit, HF hospitalization, or progression to end-stage kidney disease) was determined in patients who discontinued RAASi, down-titrated their dose by | 25%, or maintained or up-titrated their dose following the HK episode. Results A total of 15,488 and 6020 patients were included from the US and Japan, respectively. Prior to the episode of HK, 59% (US) and 27% (Japan) of patients had achieved | 50% target RAASi dose. Following the episode of HK, 33% (US) and 32% (Japan) of patients did not fill a new RAASi prescription. Risk of the cardiorenal outcome at 6 months was higher in patients who discontinued or down-titrated versus maintained or up-titrated RAASi treatment both in the US (17.5, 18.3, and 10.6%; p | 0.001) and in Japan (19.7, 20.0, and 15.1%; p | 0.001). Conclusion HK-related RAASi discontinuation or down-titration was associated with higher risk of cardiorenal events versus maintained or up-titrated RAASi.
Read more »
Japan, Netherlands, appear to join US's China chip bansBut the first rule of Chip Fight Club must be observed. Meanwhile Beijing may have its own shadow bans
Read more »